citric acid, anhydrous has been researched along with Blood Poisoning in 15 studies
Citric Acid: A key intermediate in metabolism. It is an acid compound found in citrus fruits. The salts of citric acid (citrates) can be used as anticoagulants due to their calcium chelating ability.
citric acid : A tricarboxylic acid that is propane-1,2,3-tricarboxylic acid bearing a hydroxy substituent at position 2. It is an important metabolite in the pathway of all aerobic organisms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study shows that catheter filling with a solution containing the antimicrobial taurolidine may significantly reduce the incidence of catheter-related sepsis." | 9.11 | Prevention of dialysis catheter-related sepsis with a citrate-taurolidine-containing lock solution. ( Betjes, MG; van Agteren, M, 2004) |
| "The concentration of high-dose meropenem (2 g every 8 h) administered in a prolonged infusion was similar before and after the introduction of RCA-CVVHD in patients with sepsis who developed acute kidney injury." | 7.96 | Concentration of meropenem in patients with sepsis and acute kidney injury before and after initiation of continuous renal replacement therapy: a prospective observational trial. ( Czuczwar, M; Fronczek, J; Gielicz, A; Górka, J; Kudliński, B; Nowak-Kózka, I; Polok, KJ; Seczyńska, B; Szczeklik, W, 2020) |
| "This study shows that catheter filling with a solution containing the antimicrobial taurolidine may significantly reduce the incidence of catheter-related sepsis." | 5.11 | Prevention of dialysis catheter-related sepsis with a citrate-taurolidine-containing lock solution. ( Betjes, MG; van Agteren, M, 2004) |
| "The concentration of high-dose meropenem (2 g every 8 h) administered in a prolonged infusion was similar before and after the introduction of RCA-CVVHD in patients with sepsis who developed acute kidney injury." | 3.96 | Concentration of meropenem in patients with sepsis and acute kidney injury before and after initiation of continuous renal replacement therapy: a prospective observational trial. ( Czuczwar, M; Fronczek, J; Gielicz, A; Górka, J; Kudliński, B; Nowak-Kózka, I; Polok, KJ; Seczyńska, B; Szczeklik, W, 2020) |
| " Adverse bleeding reactions were significantly less common in the citrate group compared to the heparin group, with a statistically significant difference (RR = 0." | 3.01 | Efficacy and Safety of Citric Acid and Heparin Anticoagulation in Patients with Septic Acute Kidney Injury Undergoing Continuous Renal Replacement Therapy: A Meta-Analysis. ( Cai, Q; Huang, J; Lin, S; Lin, Y; Sun, X; Xiao, M; Yao, J, 2023) |
| "During critical illness, regional anticoagulation with citrate for CRRT seems superior to heparin anticoagulation concerning tolerance and safety, mainly due to less bleeding." | 2.46 | Citrate anticoagulation for continuous renal replacement therapy in the critically ill. ( Oudemans-van Straaten, HM, 2010) |
| "Yucatan minipigs (8-15 kg) with induced septic shock underwent continuous hemodiafiltration with the CARPEDIEM™ pediatric hemodialysis system using regional citrate anticoagulation (RCA) with or without SCD (n = 5 per group)." | 1.91 | Immunomodulatory therapy using a pediatric dialysis system ameliorates septic shock in miniature pigs. ( Chan, G; Goldstein, SL; Humes, HD; Johnston, KA; Ketteler, SK; Pino, CJ, 2023) |
| "One hundred twenty two consecutive ICU cancer patients with AKI treated with citrate-based CVVHD were prospectively evaluated in this prospective observational study." | 1.48 | Use of regional citrate anticoagulation for continuous venovenous hemodialysis in critically ill cancer patients with acute kidney injury. ( Bezerra, JS; Burdmann, EA; Caires, RA; Costa E Silva, VT; Costalonga, EC; Fukushima, JT; Hajjar, LA; Oikawa, L; Oliveira Coelho, F; Oliveira, APL; Soares, CM, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (6.67) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (33.33) | 29.6817 |
| 2010's | 3 (20.00) | 24.3611 |
| 2020's | 6 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Johnston, KA | 1 |
| Pino, CJ | 1 |
| Chan, G | 1 |
| Ketteler, SK | 1 |
| Goldstein, SL | 1 |
| Humes, HD | 1 |
| van den Bosch, CH | 1 |
| Loeffen, Y | 1 |
| van der Steeg, AFW | 1 |
| van der Bruggen, JT | 1 |
| Frakking, FNJ | 1 |
| Fiocco, M | 1 |
| van de Ven, CP | 1 |
| Wijnen, MHWA | 1 |
| van de Wetering, MD | 1 |
| Lin, S | 1 |
| Xiao, M | 1 |
| Cai, Q | 1 |
| Lin, Y | 1 |
| Yao, J | 1 |
| Sun, X | 1 |
| Huang, J | 1 |
| Nowak-Kózka, I | 1 |
| Polok, KJ | 1 |
| Górka, J | 1 |
| Fronczek, J | 1 |
| Gielicz, A | 1 |
| Seczyńska, B | 1 |
| Czuczwar, M | 1 |
| Kudliński, B | 1 |
| Szczeklik, W | 1 |
| Hussein, WF | 1 |
| Gomez, N | 1 |
| Sun, SJ | 1 |
| Yu, J | 1 |
| Yang, F | 1 |
| Ajuria, M | 1 |
| Abra, GE | 1 |
| Schiller, B | 1 |
| Rhee, H | 1 |
| Berenger, B | 1 |
| Mehta, RL | 1 |
| Macedo, E | 1 |
| Costa E Silva, VT | 1 |
| Caires, RA | 1 |
| Bezerra, JS | 1 |
| Costalonga, EC | 1 |
| Oliveira, APL | 1 |
| Oliveira Coelho, F | 1 |
| Fukushima, JT | 1 |
| Soares, CM | 1 |
| Oikawa, L | 1 |
| Hajjar, LA | 1 |
| Burdmann, EA | 1 |
| Schilder, L | 1 |
| Nurmohamed, SA | 1 |
| ter Wee, PM | 1 |
| Paauw, NJ | 1 |
| Girbes, AR | 1 |
| Beishuizen, A | 1 |
| Beelen, RH | 1 |
| Groeneveld, AB | 1 |
| Oudemans-van Straaten, HM | 1 |
| Bunchman, TE | 2 |
| Maxvold, NJ | 2 |
| Brophy, PD | 1 |
| Betjes, MG | 1 |
| van Agteren, M | 1 |
| Whale, K | 1 |
| Sodemann, K | 1 |
| Polaschegg, HD | 1 |
| Feldmer, B | 1 |
| Quarello, F | 1 |
| Forneris, G | 1 |
| Barnett, J | 1 |
| Hutchings, A | 1 |
| Benfield, MR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Simplified Regional Citrate Anticoagulation Protocols for CVVH, CVVHDF and SLED Focused on the Prevention of RRT-related Hypophosphatemia and Optimization of Acid-base Balance: a Pilot Study[NCT03976440] | 30 participants (Anticipated) | Observational | 2019-06-01 | Active, not recruiting | |||
| Evaluation of a Simplified Protocol for Regional Citrate Anticoagulation in Continuous Venovenous Hemodiafiltration[NCT00583765] | 20 participants (Actual) | Observational | 2005-04-30 | Completed | |||
| Prospective, Randomized, Controlled Trial Evaluating the Efficacy of a Lock-therapy With a Solution of Taurolidine/Citrate (TauroLock) vs Standard Saline Solution for the Primary Prevention of Catheter-related Infections (CLI) in Adult Patients Wtih a Non[NCT02279121] | 162 participants (Actual) | Interventional | 2014-11-30 | Completed | |||
| A Randomised Study of Taurolock for the Locking of Tunneled Central Venous Catheters in Children With Malignant Diseases.[NCT00735813] | Phase 3 | 129 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for citric acid, anhydrous and Blood Poisoning
| Article | Year |
|---|---|
Efficacy and Safety of Citric Acid and Heparin Anticoagulation in Patients with Septic Acute Kidney Injury Undergoing Continuous Renal Replacement Therapy: A Meta-Analysis.
Topics: Acute Kidney Injury; Anticoagulants; Citrates; Citric Acid; Continuous Renal Replacement Therapy; He | 2023 |
Citrate anticoagulation for continuous renal replacement therapy in the critically ill.
Topics: Acid-Base Imbalance; Aged; Anticoagulants; Buffers; Citric Acid; Citric Acid Cycle; Clinical Protoco | 2010 |
Prevention of hemodialysis catheter-related bloodstream infection using an antimicrobial lock.
Topics: Anti-Infective Agents, Local; Catheters, Indwelling; Citric Acid; Equipment Contamination; Equipment | 2002 |
2 trials available for citric acid, anhydrous and Blood Poisoning
| Article | Year |
|---|---|
CATERPILLAR-study protocol: an assessor-blinded randomised controlled trial comparing taurolidine-citrate-heparin to heparin-only lock solutions for the prevention of central line-associated bloodstream infections in paediatric oncology patients.
Topics: Catheter-Related Infections; Central Venous Catheters; Child; Citrates; Citric Acid; Heparin; Humans | 2023 |
Prevention of dialysis catheter-related sepsis with a citrate-taurolidine-containing lock solution.
Topics: Anti-Infective Agents; Bacterial Infections; Catheterization, Central Venous; Catheters, Indwelling; | 2004 |
Prevention of dialysis catheter-related sepsis with a citrate-taurolidine-containing lock solution.
Topics: Anti-Infective Agents; Bacterial Infections; Catheterization, Central Venous; Catheters, Indwelling; | 2004 |
Prevention of dialysis catheter-related sepsis with a citrate-taurolidine-containing lock solution.
Topics: Anti-Infective Agents; Bacterial Infections; Catheterization, Central Venous; Catheters, Indwelling; | 2004 |
Prevention of dialysis catheter-related sepsis with a citrate-taurolidine-containing lock solution.
Topics: Anti-Infective Agents; Bacterial Infections; Catheterization, Central Venous; Catheters, Indwelling; | 2004 |
10 other studies available for citric acid, anhydrous and Blood Poisoning
| Article | Year |
|---|---|
Immunomodulatory therapy using a pediatric dialysis system ameliorates septic shock in miniature pigs.
Topics: Acute Kidney Injury; Animals; Anticoagulants; Citrates; Citric Acid; Immunomodulation; Renal Dialysi | 2023 |
Concentration of meropenem in patients with sepsis and acute kidney injury before and after initiation of continuous renal replacement therapy: a prospective observational trial.
Topics: Acute Kidney Injury; Aged; Anti-Bacterial Agents; Anticoagulants; Chromatography, High Pressure Liqu | 2020 |
Use of a gentamicin-citrate lock leads to lower catheter-related bloodstream infection rates and reduced cost of care in hemodialysis patients.
Topics: Catheter-Related Infections; Catheterization, Central Venous; Central Venous Catheters; Citrates; Ci | 2021 |
Regional Citrate Anticoagulation for Continuous Kidney Replacement Therapy With Calcium-Containing Solutions: A Cohort Study.
Topics: Adult; Aged; Anticoagulants; Blood Coagulation; Calcium; Citric Acid; Cohort Studies; Continuous Ren | 2021 |
Use of regional citrate anticoagulation for continuous venovenous hemodialysis in critically ill cancer patients with acute kidney injury.
Topics: Acute Kidney Injury; Aged; Anticoagulants; Calcium; Citric Acid; Critical Care; Critical Illness; El | 2018 |
Coagulation, Fibrinolysis and Inhibitors in Failing Filters during Continuous Venovenous Hemofiltration in Critically Ill Patients with Acute Kidney Injury: Effect of Anticoagulation Modalities.
Topics: Acute Kidney Injury; Adult; Aged; Aged, 80 and over; Anticoagulants; Blood Coagulation; Blood Coagul | 2015 |
Pediatric convective hemofiltration: Normocarb replacement fluid and citrate anticoagulation.
Topics: Adolescent; Anticoagulants; Bicarbonates; Child; Child, Preschool; Citric Acid; Clinical Protocols; | 2003 |
Pseudobacteraemia: a bedside fault.
Topics: Citrates; Citric Acid; Diagnostic Errors; Drug Contamination; Humans; Pseudomonas Infections; Sepsis | 1983 |
Two years' experience with Dialock and CLS (a new antimicrobial lock solution).
Topics: Adult; Anti-Infective Agents; Anticoagulants; Catheterization, Central Venous; Catheters, Indwelling | 2001 |
Pediatric hemofiltration: Normocarb dialysate solution with citrate anticoagulation.
Topics: Adolescent; Anticoagulants; Bicarbonates; Child; Child, Preschool; Citric Acid; Dialysis Solutions; | 2002 |